<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="urn:hl7-org:v3" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="312da1f3-1909-cc1d-e063-6394a90adc5e"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use PHENTERMINE HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for PHENTERMINE HYDROCHLORIDE TABLETS.
 <br/>
      <br/>
PHENTERMINE HYDROCHLORIDE tablets, for oral use, CIV
 <br/>
      <br/>
Initial U.S. Approval: 1959
</title>
   <effectiveTime value="20250325"/>
   <setId root="312d9742-6a65-c1cb-e063-6394a90a2e66"/>
   <versionNumber value="1"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="010632300"/>
            <name>NuCare Pharmaceuticals,Inc.</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="010632300"/>
                        <name>NuCare Pharmaceuticals,Inc.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C73607" displayName="relabel" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="68071-3816" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="312dd256-b6c8-e677-e063-6394a90afc85"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250325"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="68071-3816" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Phentermine Hydrochloride</name>
                        <formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Phentermine Hydrochloride</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asEquivalentEntity classCode="EQUIV">
                           <code code="C64637" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <definingMaterialKind>
                              <code code="53489-676" codeSystem="2.16.840.1.113883.6.69"/>
                           </definingMaterialKind>
                        </asEquivalentEntity>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="68401960MK" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSPOVIDONE (15 MPA.S AT 5%)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="O7TSZ97GEP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DIBASIC CALCIUM PHOSPHATE DIHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="H3R47K3TBD" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C BLUE NO. 1</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="FZ989GH94E" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POVIDONE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="30"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="0K2I505OTV" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PHENTERMINE HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="C045TQL4WP" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>PHENTERMINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="1000" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="68071-3816-1" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, PLASTIC"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20250325"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA040526" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20130812"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="white" xsi:type="CE">
                              <originalText>with blue specks</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="13" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48345" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OVAL" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="2" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">MP;273</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <policy classCode="DEADrugSchedule">
                           <code code="C48677" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CIV"/>
                        </policy>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="S1">
               <id root="312da1f3-18d6-cc1d-e063-6394a90adc5e"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>Phentermine hydrochloride is indicated as a short-term (a few weeks) adjunct in a regimen of weight reduction based on exercise, behavioral modification and caloric restriction in the management of exogenous obesity for patients with an initial body mass index ≥ 30 kg/m
 
  <sup>2</sup>, or ≥ 27 kg/m
 
  <sup>2</sup>in the presence of other risk factors (e.g., controlled hypertension, diabetes, hyperlipidemia).

 </paragraph>
                  <paragraph>Below is a chart of body mass index (BMI) based on various heights and weights.</paragraph>
                  <paragraph>BMI is calculated by taking the patient's weight, in kilograms (kg), divided by the patient's height, in meters (m), squared. Metric conversions are as follows: 
  <br/>  pounds ÷ 2.2 = kg; inches × 0.0254 = meters.
 </paragraph>
                  <table width="100%">
                     <col width="100%"/>
                     <tbody>
                        <tr>
                           <td styleCode="Toprule " valign="top">
                              <paragraph>BODY MASS INDEX (BMI), kg/m
     
      <sup>2</sup>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Botrule " valign="top">
                              <renderMultiMedia ID="id285" referencedObject="MM2"/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>The limited usefulness of agents of this class, including phentermine hydrochloride tablets, [
 
  <content styleCode="italics">see
  
   <linkHtml href="#S12.1">Clinical Pharmacology (12.1</linkHtml>,
  
   <linkHtml href="#S12.2">12.2)</linkHtml>
                     </content>] should be measured against possible risk factors inherent in their use such as those described below.

 </paragraph>
               </text>
               <effectiveTime value="20200227"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Phentermine hydrochloride is a sympathomimetic amine anorectic indicated as a short-term adjunct (a few weeks) in a regimen of weight reduction based on exercise, behavioral modification and caloric restriction in the management of exogenous obesity for patients with an initial body mass index ≥ 30 kg/m
 
    <sup>2</sup>, or ≥ 27 kg/m
 
    <sup>2</sup>in the presence of other risk factors (e.g., controlled hypertension, diabetes, hyperlipidemia). (
 
    <linkHtml href="#S1">1</linkHtml>)

   </paragraph>
                        <paragraph>The limited usefulness of agents of this class, including phentermine hydrochloride, should be measured against possible risk factors inherent in their use. (
 
    <linkHtml href="#S1">1</linkHtml>)

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <observationMedia ID="MM2">
                     <text>Figure</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="phentermine-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="S2">
               <id root="312da1f3-18d7-cc1d-e063-6394a90adc5e"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20200227"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Dosage should be individualized to obtain an adequate response with the lowest effective dose.
  
     <linkHtml href="#ID_e87840e2-540f-4b67-a30d-c6c397ac5396">(2.1)</linkHtml>
                           </item>
                           <item>Late evening administration should be avoided (risk of insomnia).
  
     <linkHtml href="#ID_e87840e2-540f-4b67-a30d-c6c397ac5396">(2.1)</linkHtml>
                           </item>
                           <item>Phentermine hydrochloride tablets can be taken with or without food.
  
     <linkHtml href="#ID_e87840e2-540f-4b67-a30d-c6c397ac5396">(2.1)</linkHtml>
                           </item>
                           <item>Limit the dosage to 15 mg daily for patients with severe renal impairment (eGFR 15 to 29 mL/min/1.73 m
  
     <sup>2</sup>)
  
     <linkHtml href="#ID_5aebc99b-f3ea-4c12-9de7-cf4722ca1208">(2.2)</linkHtml>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_e87840e2-540f-4b67-a30d-c6c397ac5396">
                     <id root="312da1f3-18d8-cc1d-e063-6394a90adc5e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Exogenous Obesity</title>
                     <text>
                        <paragraph>Dosage should be individualized to obtain an adequate response with the lowest effective dose.</paragraph>
                        <paragraph>The usual adult dose is one tablet (37.5 mg) daily, as prescribed by the physician, administered before breakfast or 1 to 2 hours after breakfast. The dosage may be adjusted to the patient’s need. For some patients, half tablet (18.75 mg) daily may be adequate, while in some cases it may be desirable to give half tablets (18.75 mg) two times a day.</paragraph>
                        <paragraph>Phentermine hydrochloride is not recommended for use in pediatric patients ≤ 16 years of age.</paragraph>
                        <paragraph>Late evening medication should be avoided because of the possibility of resulting insomnia.</paragraph>
                     </text>
                     <effectiveTime value="20200227"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_5aebc99b-f3ea-4c12-9de7-cf4722ca1208">
                     <id root="312da1f3-18d9-cc1d-e063-6394a90adc5e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Dosage in Patients With Renal Impairment</title>
                     <text>
                        <paragraph>The recommended maximum dosage of phentermine hydrochloride are 15 mg daily for patients with severe renal impairment (eGFR 15 to 29 mL min/1.73m
 
  <sup>2</sup>). Avoid use of phentermine hydrochloride in patients with eGFR less than 15 mL/min/1.73m
 
  <sup>2</sup>or end-stage renal disease requiring dialysis
 
  <content styleCode="italics">
                              <linkHtml href="#S8.6">[see Use in Specific Populations (8.6)</linkHtml>and
  
   <linkHtml href="#S12.3">Clinical Pharmacology (12.3)].</linkHtml>
                           </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20200227"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S3">
               <id root="312da1f3-18da-cc1d-e063-6394a90adc5e"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Tablets containing 37.5 mg phentermine hydrochloride (equivalent to 30 mg phentermine base).</paragraph>
               </text>
               <effectiveTime value="20200227"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Tablets containing 37.5 mg phentermine hydrochloride. (
  
     <linkHtml href="#S3">3</linkHtml>)
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S4">
               <id root="312da1f3-18db-cc1d-e063-6394a90adc5e"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <list listType="unordered">
                     <item>History of cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension)</item>
                     <item>During or within 14 days following the administration of monoamine oxidase inhibitors</item>
                     <item>Hyperthyroidism</item>
                     <item>Glaucoma</item>
                     <item>Agitated states</item>
                     <item>History of drug abuse</item>
                     <item>Pregnancy [
  
   <content styleCode="italics">see
   
    <linkHtml href="#S8.1">Use in Specific Populations (8.1)</linkHtml>
                        </content>]
 
  </item>
                     <item>Nursing [
  
   <content styleCode="italics">see
   
    <linkHtml href="#S8.3">Use in Specific Populations (8.3)</linkHtml>
                        </content>]
 
  </item>
                     <item>Known hypersensitivity, or idiosyncrasy to the sympathomimetic amines</item>
                  </list>
               </text>
               <effectiveTime value="20200227"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>History of cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension) (
  
     <linkHtml href="#S4">4</linkHtml>)
 
    </item>
                           <item>During or within 14 days following the administration of monoamine oxidase inhibitors (
  
     <linkHtml href="#S4">4</linkHtml>)
 
    </item>
                           <item>Hyperthyroidism (
  
     <linkHtml href="#S4">4</linkHtml>)
 
    </item>
                           <item>Glaucoma (
  
     <linkHtml href="#S4">4</linkHtml>)
 
    </item>
                           <item>Agitated states (
  
     <linkHtml href="#S4">4</linkHtml>)
 
    </item>
                           <item>History of drug abuse (
  
     <linkHtml href="#S4">4</linkHtml>)
 
    </item>
                           <item>Pregnancy (
  
     <linkHtml href="#S4">4</linkHtml>,
  
     <linkHtml href="#S8.1">8.1</linkHtml>)
 
    </item>
                           <item>Nursing (
  
     <linkHtml href="#S4">4</linkHtml>,
  
     <linkHtml href="#S8.3">8.3</linkHtml>)
 
    </item>
                           <item>Known hypersensitivity, or idiosyncrasy to the sympathomimetic amines (
  
     <linkHtml href="#S4">4</linkHtml>)
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S5">
               <id root="312da1f3-18dc-cc1d-e063-6394a90adc5e"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20200227"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Coadministration with other drugs for weight loss is not recommended (safety and efficacy of combination not established). (
  
     <linkHtml href="#S5.1">5.1</linkHtml>)
 
    </item>
                           <item>Rare cases of primary pulmonary hypertension have been reported. Phentermine should be discontinued in case of new, unexplained symptoms of dyspnea, angina pectoris, syncope or lower extremity edema. (
  
     <linkHtml href="#S5.2">5.2</linkHtml>)
 
    </item>
                           <item>Rare cases of serious regurgitant cardiac valvular disease have been reported. (
  
     <linkHtml href="#S5.3">5.3</linkHtml>)
 
    </item>
                           <item>Tolerance to the anorectic effect usually develops within a few weeks. If this occurs, phentermine should be discontinued. The recommended dose should not be exceeded. (
  
     <linkHtml href="#S5.4">5.4</linkHtml>)
 
    </item>
                           <item>Phentermine may impair the ability of the patient to engage in potentially hazardous activities such as operating machinery or driving a motor vehicle. (
  
     <linkHtml href="#S5.5">5.5</linkHtml>)
 
    </item>
                           <item>Risk of abuse and dependence. The least amount feasible should be prescribed or dispensed at one time in order to minimize the possibility of overdosage. (
  
     <linkHtml href="#S5.6">5.6</linkHtml>)
 
    </item>
                           <item>Concomitant alcohol use may result in an adverse drug reaction. (
  
     <linkHtml href="#S5.7">5.7</linkHtml>)
 
    </item>
                           <item>Use caution in patients with even mild hypertension (risk of increase in blood pressure). (
  
     <linkHtml href="#S5.8">5.8</linkHtml>)
 
    </item>
                           <item>A reduction in dose of insulin or oral hypoglycemic medication may be required in some patients. (
  
     <linkHtml href="#S5.9">5.9</linkHtml>)
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S5.1">
                     <id root="312da1f3-18dd-cc1d-e063-6394a90adc5e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Coadministration With Other Drug Products for Weight Loss</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Phentermine hydrochloride tablets are indicated only as short-term (a few weeks) monotherapy for the management of exogenous obesity. The safety and efficacy of combination therapy with phentermine and any other drug products for weight loss including prescribed drugs, over-the-counter preparations, and herbal products, or serotonergic agents such as selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, fluvoxamine, paroxetine), have not been established. Therefore, coadministration of phentermine and these drug products is not recommended.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20200227"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.2">
                     <id root="312da1f3-18de-cc1d-e063-6394a90adc5e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Primary Pulmonary Hypertension</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Primary Pulmonary Hypertension (PPH) – a rare, frequently fatal disease of the lungs has been reported to occur in patients receiving a combination of phentermine with fenfluramine or dexfenfluramine. The possibility of an association between PPH and the use of phentermine alone cannot be ruled out; there have been rare cases of PPH in patients who reportedly have taken phentermine alone.</content>The initial symptom of PPH is usually dyspnea. Other initial symptoms may include angina pectoris, syncope or lower extremity edema. Patients should be advised to report immediately any deterioration in exercise tolerance. Treatment should be discontinued in patients who develop new, unexplained symptoms of dyspnea, angina pectoris, syncope or lower extremity edema, and patients should be evaluated for the possible presence of pulmonary hypertension.

 </paragraph>
                     </text>
                     <effectiveTime value="20200227"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.3">
                     <id root="312da1f3-18df-cc1d-e063-6394a90adc5e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Valvular Heart Disease</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Serious regurgitant cardiac valvular disease, primarily affecting the mitral, aortic and/or tricuspid valves, has been reported in otherwise healthy persons who had taken a combination of phentermine with fenfluramine or dexfenfluramine for weight loss. The possible role of phentermine in the etiology of these valvulopathies has not been established and their course in individuals after the drugs are stopped is not known. The possibility of an association between valvular heart disease and the use of phentermine alone cannot be ruled out; there have been rare cases of valvular heart disease in patients who reportedly have taken phentermine alone.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20200227"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.4">
                     <id root="312da1f3-18e0-cc1d-e063-6394a90adc5e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Development of Tolerance, Discontinuation in Case of Tolerance</title>
                     <text>
                        <paragraph>When tolerance to the anorectant effect develops, the recommended dose should not be exceeded in an attempt to increase the effect; rather, the drug should be discontinued.</paragraph>
                     </text>
                     <effectiveTime value="20200227"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.5">
                     <id root="312da1f3-18e1-cc1d-e063-6394a90adc5e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5 Effect on the Ability to Engage in Potentially Hazardous Tasks</title>
                     <text>
                        <paragraph>Phentermine may impair the ability of the patient to engage in potentially hazardous activities such as operating machinery or driving a motor vehicle; the patient should therefore be cautioned accordingly.</paragraph>
                     </text>
                     <effectiveTime value="20200227"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.6">
                     <id root="312da1f3-18e2-cc1d-e063-6394a90adc5e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6 Risk of Abuse and Dependence</title>
                     <text>
                        <paragraph>Phentermine is related chemically and pharmacologically to amphetamine (d- and d/l-amphetamine) and to other related stimulant drugs that have been extensively abused. The possibility of abuse of phentermine should be kept in mind when evaluating the desirability of including a drug as part of a weight reduction program. See
 
  <content styleCode="italics">
                              <linkHtml href="#S9">Drug Abuse and Dependence (9)</linkHtml>and
  
   <linkHtml href="#S10">Overdosage (10)</linkHtml>
                           </content>.

 </paragraph>
                        <paragraph>The least amount feasible should be prescribed or dispensed at one time in order to minimize the possibility of overdosage.</paragraph>
                     </text>
                     <effectiveTime value="20200227"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.7">
                     <id root="312da1f3-18e3-cc1d-e063-6394a90adc5e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.7 Usage With Alcohol</title>
                     <text>
                        <paragraph>Concomitant use of alcohol with phentermine may result in an adverse drug reaction.</paragraph>
                     </text>
                     <effectiveTime value="20200227"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.8">
                     <id root="312da1f3-18e4-cc1d-e063-6394a90adc5e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.8 Use in Patients With Hypertension</title>
                     <text>
                        <paragraph>Use caution in prescribing phentermine for patients with even mild hypertension (risk of increase in blood pressure).</paragraph>
                     </text>
                     <effectiveTime value="20200227"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.9">
                     <id root="312da1f3-18e5-cc1d-e063-6394a90adc5e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.9 Use in Patients on Insulin or Oral Hypoglycemic Medications for Diabetes Mellitus</title>
                     <text>
                        <paragraph>A reduction in insulin or oral hypoglycemic medications in patients with diabetes mellitus may be required.</paragraph>
                     </text>
                     <effectiveTime value="20200227"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S6">
               <id root="312da1f3-18e6-cc1d-e063-6394a90adc5e"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following adverse reactions are described, or described in greater detail, in other sections:</paragraph>
                  <list listType="unordered">
                     <item>Primary pulmonary hypertension [
  
   <content styleCode="italics">see
   
    <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>
                        </content>]
 
  </item>
                     <item>Valvular heart disease [
  
   <content styleCode="italics">see
   
    <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>
                        </content>]
 
  </item>
                     <item>Effect on the ability to engage in potentially hazardous tasks [
  
   <content styleCode="italics">see
   
    <linkHtml href="#S5.5">Warnings and Precautions (5.5)</linkHtml>
                        </content>]
 
  </item>
                     <item>Withdrawal effects following prolonged high dosage administration [
  
   <content styleCode="italics">see
   
    <linkHtml href="#S9.3">Drug Abuse and Dependence (9.3)</linkHtml>
                        </content>]
 
  </item>
                  </list>
                  <paragraph>The following adverse reactions to phentermine have been identified:</paragraph>
                  <paragraph>
                     <content styleCode="underline">Cardiovascular</content>
                  </paragraph>
                  <paragraph>Primary pulmonary hypertension and/or regurgitant cardiac valvular disease, palpitation, tachycardia, elevation of blood pressure, ischemic events.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Central Nervous System</content>
                  </paragraph>
                  <paragraph>Overstimulation, restlessness, dizziness, insomnia, euphoria, dysphoria, tremor, headache, psychosis.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Gastrointestinal</content>
                  </paragraph>
                  <paragraph>Dryness of the mouth, unpleasant taste, diarrhea, constipation, other gastrointestinal disturbances.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Allergic</content>
                  </paragraph>
                  <paragraph>Urticaria.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Endocrine</content>
                  </paragraph>
                  <paragraph>Impotence, changes in libido.</paragraph>
               </text>
               <effectiveTime value="20200227"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Adverse events have been reported in the cardiovascular, central nervous, gastrointestinal, allergic, and endocrine systems. (
 
    <linkHtml href="#S6">6</linkHtml>)

   </paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Sun Pharmaceutical Industries, Inc. at 1-800-406-7984 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S7">
               <id root="312da1f3-18e7-cc1d-e063-6394a90adc5e"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <effectiveTime value="20200227"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Monoamine oxidase inhibitors: Risk of hypertensive crisis. (
  
     <linkHtml href="#S4">4</linkHtml>,
  
     <linkHtml href="#S7.1">7.1</linkHtml>)
 
    </item>
                           <item>Alcohol: Consider potential interaction. (
  
     <linkHtml href="#S7.2">7.2</linkHtml>)
 
    </item>
                           <item>Insulin and oral hypoglycemics: Requirements may be altered. (
  
     <linkHtml href="#S7.3">7.3</linkHtml>)
 
    </item>
                           <item>Adrenergic neuron blocking drugs: Hypotensive effect may be decreased by phentermine. (
  
     <linkHtml href="#S7.4">7.4</linkHtml>)
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S7.1">
                     <id root="312da1f3-18e8-cc1d-e063-6394a90adc5e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1 Monoamine Oxidase Inhibitors</title>
                     <text>
                        <paragraph>Use of phentermine is contraindicated during or within 14 days following the administration of monoamine oxidase inhibitors because of the risk of hypertensive crisis
 
  <content styleCode="italics">.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20200227"/>
                  </section>
               </component>
               <component>
                  <section ID="S7.2">
                     <id root="312da1f3-18e9-cc1d-e063-6394a90adc5e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.2 Alcohol</title>
                     <text>
                        <paragraph>Concomitant use of alcohol with phentermine may result in an adverse drug reaction
 
  <content styleCode="italics">.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20200227"/>
                  </section>
               </component>
               <component>
                  <section ID="S7.3">
                     <id root="312da1f3-18ea-cc1d-e063-6394a90adc5e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.3 Insulin and Oral Hypoglycemic Medications</title>
                     <text>
                        <paragraph>Requirements may be altered [
 
  <content styleCode="italics">see
  
   <linkHtml href="#S5.9">Warnings and Precautions (5.9)</linkHtml>
                           </content>].

 </paragraph>
                     </text>
                     <effectiveTime value="20200227"/>
                  </section>
               </component>
               <component>
                  <section ID="S7.4">
                     <id root="312da1f3-18eb-cc1d-e063-6394a90adc5e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.4 Adrenergic Neuron Blocking Drugs</title>
                     <text>
                        <paragraph>Phentermine may decrease the hypotensive effect of adrenergic neuron blocking drugs.</paragraph>
                     </text>
                     <effectiveTime value="20200227"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S8">
               <id root="312da1f3-18ec-cc1d-e063-6394a90adc5e"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20200227"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Nursing mothers: Discontinue drug or nursing taking into consideration importance of drug to mother. (
  
     <linkHtml href="#S4">4</linkHtml>,
  
     <linkHtml href="#S8.3">8.3</linkHtml>)
 
    </item>
                           <item>Pediatric use: Safety and effectiveness not established. (
  
     <linkHtml href="#S8.4">8.4</linkHtml>)
 
    </item>
                           <item>Geriatric use: Due to substantial renal excretion, use with caution. (
  
     <linkHtml href="#S8.5">8.5</linkHtml>)
 
    </item>
                           <item>Renal Impairment: Avoid use in patients with eGFR less than 15 mL/min/1.73m
  
     <sup>2</sup>or end-stage renal disease requiring dialysis.
  
     <linkHtml href="#S8.6">(8.6)</linkHtml>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S8.1">
                     <id root="312da1f3-18ed-cc1d-e063-6394a90adc5e"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Pregnancy Category X</content>
                        </paragraph>
                        <paragraph>Phentermine is contraindicated during pregnancy because weight loss offers no potential benefit to a pregnant woman and may result in fetal harm. A minimum weight gain, and no weight loss, is currently recommended for all pregnant women, including those who are already overweight or obese, due to obligatory weight gain that occurs in maternal tissues during pregnancy. Phentermine has pharmacologic activity similar to amphetamine (d- and d
 
  <content styleCode="italics">/</content>l-amphetamine) [
 
  <content styleCode="italics">see
  
   <linkHtml href="#S12.1">Clinical Pharmacology (12.1)</linkHtml>
                           </content>]. Animal reproduction studies have not been conducted with phentermine. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus.

 </paragraph>
                     </text>
                     <effectiveTime value="20200227"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.3">
                     <id root="312da1f3-18ee-cc1d-e063-6394a90adc5e"/>
                     <code code="34080-2" codeSystem="2.16.840.1.113883.6.1" displayName="NURSING MOTHERS SECTION"/>
                     <title>8.3 Nursing Mothers</title>
                     <text>
                        <paragraph>It is not known if phentermine is excreted in human milk; however, other amphetamines are present in human milk. Because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</paragraph>
                     </text>
                     <effectiveTime value="20200227"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.4">
                     <id root="312da1f3-18ef-cc1d-e063-6394a90adc5e"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>Safety and effectiveness in pediatric patients have not been established. Because pediatric obesity is a chronic condition requiring long-term treatment, the use of this product, approved for short-term therapy, is not recommended.</paragraph>
                     </text>
                     <effectiveTime value="20200227"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.5">
                     <id root="312da1f3-18f0-cc1d-e063-6394a90adc5e"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</paragraph>
                        <paragraph>This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.</paragraph>
                     </text>
                     <effectiveTime value="20200227"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.6">
                     <id root="312da1f3-18f1-cc1d-e063-6394a90adc5e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.6 Renal Impairment</title>
                     <text>
                        <paragraph>Based on the reported excretion of phentermine in urine, exposure increases can be expected in patients with renal impairment. [
 
  <content styleCode="italics">see
  
   <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>
                           </content>].

 </paragraph>
                        <paragraph>Use caution when administering phentermine to patients with renal impairment. In patients with severe renal impairment (eGFR 15 to 29 mL/min/1.73m
 
  <sup>2</sup>), limit the dosage of phentermine to 15 mg daily
 
  <content styleCode="italics">
                              <linkHtml href="#ID_5aebc99b-f3ea-4c12-9de7-cf4722ca1208">[see Dosage and Administration (2.2)].</linkHtml>
                           </content>Phentermine has not been studied in patients with eGFR less than 15 mL/min/1.73m
 
  <sup>2</sup>, including end-stage renal disease requiring dialysis; avoid use in these populations.

 </paragraph>
                     </text>
                     <effectiveTime value="20200227"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S9">
               <id root="312da1f3-18f2-cc1d-e063-6394a90adc5e"/>
               <code code="42227-9" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG ABUSE AND DEPENDENCE SECTION"/>
               <title>9 DRUG ABUSE AND DEPENDENCE</title>
               <effectiveTime value="20200227"/>
               <component>
                  <section ID="S9.1">
                     <id root="312da1f3-18f3-cc1d-e063-6394a90adc5e"/>
                     <code code="34085-1" codeSystem="2.16.840.1.113883.6.1" displayName="CONTROLLED SUBSTANCE SECTION"/>
                     <title>9.1 Controlled Substance</title>
                     <text>
                        <paragraph>Phentermine is a Schedule IV controlled substance.</paragraph>
                     </text>
                     <effectiveTime value="20200227"/>
                  </section>
               </component>
               <component>
                  <section ID="S9.2">
                     <id root="312da1f3-18f4-cc1d-e063-6394a90adc5e"/>
                     <code code="34086-9" codeSystem="2.16.840.1.113883.6.1" displayName="ABUSE SECTION"/>
                     <title>9.2 Abuse</title>
                     <text>
                        <paragraph>Phentermine is related chemically and pharmacologically to the amphetamines. Amphetamines and other stimulant drugs have been extensively abused and the possibility of abuse of phentermine should be kept in mind when evaluating the desirability of including a drug as part of a weight reduction program.</paragraph>
                     </text>
                     <effectiveTime value="20200227"/>
                  </section>
               </component>
               <component>
                  <section ID="S9.3">
                     <id root="312da1f3-18f5-cc1d-e063-6394a90adc5e"/>
                     <code code="34087-7" codeSystem="2.16.840.1.113883.6.1" displayName="DEPENDENCE SECTION"/>
                     <title>9.3 Dependence</title>
                     <text>
                        <paragraph>Abuse of amphetamines and related drugs may be associated with intense psychological dependence and severe social dysfunction. There are reports of patients who have increased the dosage of these drugs to many times than recommended. Abrupt cessation following prolonged high dosage administration results in extreme fatigue and mental depression; changes are also noted on the sleep EEG. Manifestations of chronic intoxication with anorectic drugs include severe dermatoses, marked insomnia, irritability, hyperactivity and personality changes. A severe manifestation of chronic intoxication is psychosis, often clinically indistinguishable from schizophrenia.</paragraph>
                     </text>
                     <effectiveTime value="20200227"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S10">
               <id root="312da1f3-18f6-cc1d-e063-6394a90adc5e"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph>The least amount feasible should be prescribed or dispensed at one time in order to minimize the possibility of overdosage.</paragraph>
               </text>
               <effectiveTime value="20200227"/>
               <component>
                  <section ID="ID_e8b2f6dc-29a2-4536-a1e2-eb7ed46c6443">
                     <id root="312da1f3-18f7-cc1d-e063-6394a90adc5e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>10.1 Acute Overdosage</title>
                     <text>
                        <paragraph>Manifestations of acute overdosage include restlessness, tremor, hyperreflexia, rapid respiration, confusion, assaultiveness, hallucinations, and panic states. Fatigue and depression usually follow the central stimulation. Cardiovascular effects include tachycardia, arrhythmia, hypertension or hypotension, and circulatory collapse. Gastrointestinal symptoms include nausea, vomiting, diarrhea and abdominal cramps. Overdosage of pharmacologically similar compounds has resulted in fatal poisoning usually terminates in convulsions and coma.</paragraph>
                        <paragraph>Management of acute phentermine hydrochloride intoxication is largely symptomatic and includes lavage and sedation with a barbiturate. Experience with hemodialysis or peritoneal dialysis is inadequate to permit recommendations in this regard. Acidification of the urine increases phentermine excretion. Intravenous phentolamine (Regitine
 
  <sup>®</sup>, CIBA) has been suggested on pharmacologic grounds for possible acute, severe hypertension, if this complicates overdosage.

 </paragraph>
                     </text>
                     <effectiveTime value="20200227"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_36027f16-0c29-46b1-b725-51dfaf4ffe2a">
                     <id root="312da1f3-18f8-cc1d-e063-6394a90adc5e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>10.2 Chronic Intoxication</title>
                     <text>
                        <paragraph>Manifestations of chronic intoxication with anorectic drugs include severe dermatoses, marked insomnia, irritability, hyperactivity and personality changes. The most severe manifestation of chronic intoxications is psychosis, often clinically indistinguishable from schizophrenia. See
 
  <content styleCode="italics">
                              <linkHtml href="#S9.3">Drug Abuse and Dependence (9.3)</linkHtml>
                           </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20200227"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S11">
               <id root="312da1f3-18f9-cc1d-e063-6394a90adc5e"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>Phentermine hydrochloride USP has the chemical name of α,α,-Dimethylphenethylamine hydrochloride. The structural formula is as follows:</paragraph>
                  <renderMultiMedia ID="id787" referencedObject="MM1"/>
                  <paragraph>Phentermine hydrochloride is a white, odorless, hygroscopic, crystalline powder which is soluble in water and lower alcohols, slightly soluble in chloroform and insoluble in ether.</paragraph>
                  <paragraph>Phentermine hydrochloride, an anorectic agent for oral administration, is available as a tablet containing 37.5 mg of phentermine hydrochloride (equivalent to 30 mg of phentermine base).</paragraph>
                  <paragraph>Phentermine hydrochloride tablets contain the inactive ingredients: crospovidone, dibasic calcium phosphate dihydrate, FD&amp;C Blue #1, magnesium stearate, and povidone.</paragraph>
               </text>
               <effectiveTime value="20200227"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Chemical Structure</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="phentermine-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="S12">
               <id root="312da1f3-18fa-cc1d-e063-6394a90adc5e"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20200227"/>
               <component>
                  <section ID="S12.1">
                     <id root="312da1f3-18fb-cc1d-e063-6394a90adc5e"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Phentermine is a sympathomimetic amine with pharmacologic activity similar to the prototype drugs of this class used in obesity, amphetamine (d- and d
 
  <content styleCode="italics">/</content>l-amphetamine). Drugs of this class used in obesity are commonly known as "anorectics" or "anorexigenics." It has not been established that the primary action of such drugs in treating obesity is one of appetite suppression since other central nervous system actions, or metabolic effects, may also be involved.

 </paragraph>
                     </text>
                     <effectiveTime value="20200227"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.2">
                     <id root="312da1f3-18fc-cc1d-e063-6394a90adc5e"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph>Typical actions of amphetamines include central nervous system stimulation and elevation of blood pressure. Tachyphylaxis and tolerance have been demonstrated with all drugs of this class in which these phenomena have been looked for.</paragraph>
                     </text>
                     <effectiveTime value="20200227"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.3">
                     <id root="312da1f3-18fd-cc1d-e063-6394a90adc5e"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>Following the administration of phentermine, phentermine reaches peak concentrations (C
 
  <sub>max</sub>) after 3 to 4.4 hours.

 </paragraph>
                     </text>
                     <effectiveTime value="20200227"/>
                     <component>
                        <section ID="ID_9d7229f5-5278-4a03-8e7c-00a84c02ad34">
                           <id root="312da1f3-18fe-cc1d-e063-6394a90adc5e"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Specific Populations</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20200227"/>
                           <component>
                              <section ID="ID_517d67da-d937-493b-acb4-f55740731778">
                                 <id root="312da1f3-18ff-cc1d-e063-6394a90adc5e"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Renal Impairment</content>
                                    </paragraph>
                                    <paragraph>Cumulative urinary excretion of phentermine under uncontrolled urinary pH conditions was 62% to 85%.</paragraph>
                                    <paragraph>Systemic exposure of phentermine may increase up to 91%, 45%, and 22% in patients with severe, moderate, and mild renal impairment, respectively
 
  <content styleCode="italics">[see Dosage and Administration (2.2) and Use in Specific Populations (8.6)].</content>
                                    </paragraph>
                                 </text>
                                 <effectiveTime value="20200227"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section ID="ID_2ebeb015-53de-40a3-9d18-1caeefb72c78">
                           <id root="312da1f3-1900-cc1d-e063-6394a90adc5e"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Drug Interactions</content>
                              </paragraph>
                              <paragraph>In a single-dose study comparing the exposures after oral administration of a combination capsule of 15 mg phentermine and 92 mg topiramate to the exposures after oral administration of a 15 mg phentermine capsule or a 92 mg topiramate capsule, there is no significant topiramate exposure change in the presence of phentermine. However in the presence of topiramate, phentermine C
 
  <sub>max</sub>and AUC increase 13% and 42%, respectively.

 </paragraph>
                           </text>
                           <effectiveTime value="20200227"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S13">
               <id root="312da1f3-1901-cc1d-e063-6394a90adc5e"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20200227"/>
               <component>
                  <section ID="S13.1">
                     <id root="312da1f3-1902-cc1d-e063-6394a90adc5e"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>Studies have not been performed with phentermine to determine the potential for carcinogenesis, mutagenesis or impairment of fertility.</paragraph>
                     </text>
                     <effectiveTime value="20200227"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S14">
               <id root="312da1f3-1903-cc1d-e063-6394a90adc5e"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <text>
                  <paragraph>In relatively short-term clinical trials, adult obese subjects instructed in dietary management and treated with "anorectic" drugs lost more weight on the average than those treated with placebo and diet.</paragraph>
                  <paragraph>The magnitude of increased weight loss of drug-treated patients over placebo-treated patients is only a fraction of a pound a week. The rate of weight loss is greatest in the first weeks of therapy for both drug and placebo subjects and tends to decrease in succeeding weeks. The possible origins of the increased weight loss due to the various drug effects are not established. The amount of weight loss associated with the use of an "anorectic" drug varies from trial to trial, and the increased weight loss appears to be related in part to variables other than the drugs prescribed, such as the physician-investigator, the population treated and the diet prescribed. Studies do not permit conclusions as to the relative importance of the drug and non-drug factors on weight loss.</paragraph>
                  <paragraph>The natural history of obesity is measured over several years, whereas the studies cited are restricted to a few weeks' duration; thus, the total impact of drug-induced weight loss over that of diet alone must be considered clinically limited.</paragraph>
               </text>
               <effectiveTime value="20200227"/>
            </section>
         </component>
         <component>
            <section ID="S16">
               <id root="312db3af-9dd3-d5e4-e063-6394a90af999"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>Phentermine hydrochloride tablets USP 37.5 mg (equivalent to 30 mg phentermine base) are white with blue specks, oval shaped, scored on one side and debossed MP 273 on the other side.</paragraph>
                  <table width="59.02%">
                     <colgroup>
                        <col width="30%"/>
                        <col width="39%"/>
                     </colgroup>
                     <tbody>
                        <tr>
                           <td styleCode="Botrule " valign="top">
                              <paragraph>Bottles of 1000</paragraph>
                           </td>
                           <td styleCode="Botrule " valign="top">
                              <paragraph>NDC 68071-3816-1</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20200227"/>
               <component>
                  <section ID="ID_487243e3-36d9-4fce-9d6f-5baaacb3f8b0">
                     <id root="312da1f3-1905-cc1d-e063-6394a90adc5e"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <text>
                        <paragraph>Store at 20° to 25°C (68° to 77°F). 
  <br/>  [See USP Controlled Room Temperature]
 </paragraph>
                        <paragraph>DISPENSE IN TIGHT, LIGHT-RESISTANT CONTAINER.</paragraph>
                        <paragraph>Keep out of the reach of children.</paragraph>
                     </text>
                     <effectiveTime value="20200227"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S17">
               <id root="312da1f3-1906-cc1d-e063-6394a90adc5e"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>Patients must be informed that phentermine hydrochloride is a
 
  <content styleCode="italics">short-term</content>(a few weeks) adjunct in a regimen of weight reduction based on exercise, behavioral modification and caloric restriction in the management of exogenous obesity, and that coadministration of phentermine with other drugs for weight loss is not recommended [
 
  <content styleCode="italics">see
  
   <linkHtml href="#S1">Indications and Usage (1)</linkHtml>and
  
   <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>
                     </content>].

 </paragraph>
                  <paragraph>Patients must be instructed on how much phentermine to take, and when and how to take it [
 
  <content styleCode="italics">see
  
   <linkHtml href="#S2">Dosage and Administration (2)</linkHtml>
                     </content>].

 </paragraph>
                  <paragraph>Advise pregnant women and nursing mothers not to use phentermine [
 
  <content styleCode="italics">see
  
   <linkHtml href="#S8.1">Use in Specific Populations (8.1</linkHtml>,
  
   <linkHtml href="#S8.3">8.3)</linkHtml>
                     </content>].

 </paragraph>
                  <paragraph>Patients must be informed about the risks of use of phentermine (including the risks discussed in Warnings and Precautions), about the symptoms of potential adverse reactions and when to contact a physician and/or take other action. The risks include, but are not limited to:</paragraph>
                  <list listType="unordered">
                     <item>Development of primary pulmonary hypertension [
  
   <content styleCode="italics">see
   
    <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>
                        </content>]
 
  </item>
                     <item>Development of serious valvular heart disease [
  
   <content styleCode="italics">see
   
    <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>
                        </content>]
 
  </item>
                     <item>Effects on the ability to engage in potentially hazardous tasks [
  
   <content styleCode="italics">see
   
    <linkHtml href="#S5.5">Warnings and Precautions (5.5)</linkHtml>
                        </content>]
 
  </item>
                     <item>The risk of an increase in blood pressure [
  
   <content styleCode="italics">see
   
    <linkHtml href="#S5.8">Warnings and Precautions (5.8)</linkHtml>and
   
    <linkHtml href="#S6">Adverse Reactions (6)</linkHtml>
                        </content>]
 
  </item>
                     <item>The risk of interactions [
  
   <content styleCode="italics">see
   
    <linkHtml href="#S4">Contraindications (4)</linkHtml>,
   
    <linkHtml href="#S5.7">Warnings and Precautions (5.7</linkHtml>,
   
    <linkHtml href="#S5.9">5.9)</linkHtml>and
   
    <linkHtml href="#S7">Drug Interactions (7)</linkHtml>
                        </content>]
 
  </item>
                  </list>
                  <paragraph>See also, for example,
 
  <content styleCode="italics">
                        <linkHtml href="#S6">Adverse Reactions (6)</linkHtml>
                     </content>and
 
  <content styleCode="italics">
                        <linkHtml href="#S8">Use in Specific Populations (8)</linkHtml>
                     </content>.

 </paragraph>
                  <paragraph>The patients must also be informed about</paragraph>
                  <list listType="unordered">
                     <item>the potential for developing tolerance and actions if they suspect development of tolerance [
  
   <content styleCode="italics">see
   
    <linkHtml href="#S5.4">Warnings and Precautions (5.4)</linkHtml>
                        </content>] and
 
  </item>
                     <item>the risk of dependence and the potential consequences of abuse [
  
   <content styleCode="italics">see
   
    <linkHtml href="#S5.6">Warnings and Precautions (5.6)</linkHtml>,
   
    <linkHtml href="#S9">Drug Abuse and Dependence (9)</linkHtml>, and
   
    <linkHtml href="#S10">Overdosage (10)</linkHtml>
                        </content>].
 
  </item>
                  </list>
                  <paragraph>Tell patients to keep phentermine in a safe place to prevent theft, accidental overdose, misuse or abuse. Selling or giving away phentermine may harm others and is against the law.</paragraph>
                  <paragraph>Regitine
 
  <sup>®</sup>is a registered trademark of CIBA PHARMACEUTICAL PRODUCTS, INC.

 </paragraph>
                  <paragraph>
                     <content styleCode="bold">Distributed by:</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Sun Pharmaceutical Industries, Inc.</content>
                     <br/>
                     <content styleCode="bold">Cranbury, NJ 08512</content>
                  </paragraph>
                  <paragraph>Rev 14, September 2017</paragraph>
               </text>
               <effectiveTime value="20200227"/>
            </section>
         </component>
         <component>
            <section ID="ID_3f6b0e9f-f994-440a-ae4e-409a0a6f6dc8">
               <id root="312dbbd7-731d-a4f7-e063-6294a90a682b"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL</title>
               <text>
                  <paragraph>
                     <renderMultiMedia referencedObject="img_312d932b-8d85-92bb-e063-6294a90a7a1b"/>
                  </paragraph>
               </text>
               <effectiveTime value="20250325"/>
               <component>
                  <observationMedia ID="img_312d932b-8d85-92bb-e063-6294a90a7a1b">
                     <text>pdp</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="68071-3816-1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>